ArticleCancer research2008
p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers.
Article in Cancer research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 58 citations in OpenAlex.
- Estrogen and viral infection.Frontiers in immunology · 2025Review
- Translation Initiation Factor-2S2 (eIF2S2) Contributes to Cervical Carcinogenesis by Inhibiting the TGF-β/SMAD4 Signaling Pathway.Biomolecules & therapeutics · 2024Article
- HPV and Cervical Cancer: Molecular and Immunological Aspects, Epidemiology and Effect of Vaccination in Latin American Women.Viruses · 2024Review
- SERMs suppresses the growth of ERα positive cervical cancer xenografts through predominant inhibition of extra-nuclear ERα expression.American journal of cancer research · 2021Article
- The role of Hippo-YAP signaling in squamous cell carcinomas.Cancer science · 2021Review
- Endogenous YAP1 activation drives immediate onset of cervical carcinoma in situ in mice.Cancer science · 2020Article
- Human papilloma virus (HPV) profiles in breast cancer: future management.Annals of translational medicine · 2020Review
- Association of breast cancer with human papillomavirus (HPV) infection in Northeast Brazil: molecular evidence.Clinics (Sao Paulo, Brazil) · 2018Article
- ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function.Oncotarget · 2018Article
- Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis.Breast cancer research : BCR · 2017Article
- Recurrence of cervical cancer and its resistance to progestin therapy in a mouse model.Oncotarget · 2017Article
- Evolution of malignant plasmacytoma cell lines from K14E7 Fancd2-/- mouse long-term bone marrow cultures.Oncotarget · 2016Article
- Article
- Illuminating p53 function in cancer with genetically engineered mouse models.Seminars in cell & developmental biology · 2014Review
- Article
- The p53-estrogen receptor loop in cancer.Current molecular medicine · 2013Review
- The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter.The Journal of experimental medicine · 2013Article
- Requirement for stromal estrogen receptor alpha in cervical neoplasia.Hormones & cancer · 2013Article
- Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.Molecular cancer therapeutics · 2013Article
- Emerging theme: cellular PDZ proteins as common targets of pathogenic viruses.Journal of virology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Whereas the tumor suppressor p53 gene is frequently mutated in most human cancers, this is not the case in human papillomavirus (HPV)-associated cancers, presumably because the viral E6 oncoprotein inactivates the p53 protein. The ability of E6 to transform cells in tissue culture and induce cancers in mice correlates in part with its ability to inactivate p53. In this study, we compared the expression of the HPV16 E6 oncogene to the conditional genetic disruption of p53 in the context of a mouse model for cervical cancer in which estrogen is a critical cofactor. Nearly all of the K14Crep53(f/f) mice treated with estrogen developed cervical cancer, a stark contrast to its complete absence in like-treated K14E6(WT)p53(f/f) mice, indicating that HPV16 E6 must only partially inactivate p53. p53-independent activities of E6 also contributed to carcinogenesis, but in the female reproductive tract, these activities were manifested only in the presence of the HPV16 E7 oncogene. Interestingly, treatment of K14Crep53(f/f) mice with estrogen also resulted in mammary tumors after only a short latency, many of which were positive for estrogen receptor alpha. The majority of these mammary tumors were of mixed cell types, suggestive of their originating from a multipotent progenitor. Furthermore, a subset of mammary tumors arising in the estrogen-treated, p53-deficient mammary glands exhibited evidence of an epithelial to mesenchymal transition. These data show the importance of the synergy between estrogen and p53 insufficiency in determining basic properties of carcinogenesis in hormone-responsive tissues, such as the breast and the reproductive tract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.